WO2014112530A1 - 5-ヒドロキシ-1h-イミダゾール-4-カルボキサミドを含有する錠剤 - Google Patents
5-ヒドロキシ-1h-イミダゾール-4-カルボキサミドを含有する錠剤 Download PDFInfo
- Publication number
- WO2014112530A1 WO2014112530A1 PCT/JP2014/050591 JP2014050591W WO2014112530A1 WO 2014112530 A1 WO2014112530 A1 WO 2014112530A1 JP 2014050591 W JP2014050591 W JP 2014050591W WO 2014112530 A1 WO2014112530 A1 WO 2014112530A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tablet
- manufactured
- hydrate
- silicon dioxide
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Definitions
- the present invention relates to a tablet containing (1) 5-hydroxy-1H-imidazole-4-carboxamide or a salt or hydrate thereof and (2) silicon dioxide.
- 5-Hydroxy-1H-imidazole-4-carboxamide (hereinafter also referred to as Compound A) or a salt thereof or a hydrate thereof is a medically useful compound as an anticancer agent since it has a potent anticancer activity (Patent Literature) 1).
- it is a highly safe anticancer agent that exerts a powerful effect on solid cancer, which has been difficult to treat with chemical treatment, and has few side effects. It is widely used for oral, injection, ointment, suppository, etc. It is a compound that is expected to have clinical application in various dosage forms. Tablets containing Compound A or a salt thereof or a hydrate thereof are orally administered in 1 to several tablets.
- Non-patent Document 1 the size of easy-to-drink round tablets is 7-8 mm in diameter, and the size of easy-to-drink elliptical tablets is 9 mm in major axis.
- Non-patent Document 3 A method is known in which a binder is used and the active ingredient content is increased by a wet granulation method (Non-patent Document 3). Further, the hardness can be increased by using a tableting powder granulated by a dry or wet granulation method and strengthening the bonding force between the particles during tableting.
- the additive content is required to be above a certain level in the direct tableting method, and the tablet size increases as the active ingredient content increases.
- large tablets of 9 mm or more are difficult to take for children and patients who have difficulty in swallowing, as well as normal adult patients, because they have a sense of resistance and pressure, leading to reduced compliance.
- the method of increasing the binding force between the particles at the time of tableting can obtain the required hardness, but the elution property decreases due to the increase in the binding force between the particles.
- the present invention provides the following.
- the additive is an additive containing a disintegrant.
- the silicon dioxide is one or more selected from silica gel, anhydrous silicic acid, colloidal silicon dioxide, light anhydrous silicic acid, and hydrous silicon dioxide, [1] to [3] Tablets.
- the disintegrant is one or more selected from cellulose derivatives, starch derivatives and polyvinylpyrrolidone derivatives.
- the disintegrant is one or more selected from carmellose calcium, carmellose, low-substituted hydroxypropylcellulose, croscarmellose sodium, sodium carboxymethyl starch, partially pregelatinized starch, and crospovidone [3] Tablet as described in 1.
- the silicon dioxide is one or more selected from silica gel, anhydrous silicic acid, colloidal silicon dioxide, light anhydrous silicic acid and hydrous silicon dioxide, [14] to [16] Tablets.
- the tablet of the present invention has a high content of Compound A or a salt thereof or a hydrate thereof, the tablet size is easy to take, and the dissolution property is excellent.
- the present invention is described in detail below.
- The% used in the present invention means mass percentage unless otherwise specified.
- a numerical range indicated by using “to” indicates a range including the numerical values described before and after “to” as the minimum value and the maximum value, respectively.
- the amount of each component in the composition means the total amount of the plurality of substances present in the composition unless there is a specific notice when there are a plurality of substances corresponding to each component in the composition. To do.
- the term “compound A or a salt thereof or a hydrate thereof” when referring to the compound A (same as “5-hydroxy-1H-imidazole-4-carboxamide”), the term “compound A or a salt thereof or a hydrate thereof” unless otherwise specified. It is intended to indicate any one selected from the group consisting of compound A, a salt of compound A, a hydrate of compound A, and a hydrate of a salt of compound A, and “compound A or a salt thereof or a hydration thereof” Unless otherwise specified, includes at least one selected from the group consisting of Compound A, Compound A salt, Compound A hydrate, and Compound A salt hydrate, unless otherwise specified. It means being.
- Compound A or a salt thereof or a hydrate thereof used in the present invention can be produced, for example, by the method described in Production Example 1 described later.
- the content of compound A or a salt thereof or a hydrate thereof can be 0.3 to 95% of the tablet mass, preferably 20 to 90%, more preferably 40 to 85%.
- the silicon dioxide used in the present invention can be blended in and / or outside the granulated powder.
- the content of silicon dioxide can be 0.1 to 20% of the tablet mass, preferably 0.5 to 15%, more preferably 1 to 5%.
- the content of silicon dioxide is preferably 0.3 to 3% of the tablet mass.
- tablette mass refers to the mass of a tablet before coating, unless otherwise specified, for a film-coated tablet.
- Examples of silicon dioxide include, but are not limited to, silica gel, anhydrous silicic acid, colloidal silicon dioxide, light anhydrous silicic acid, and hydrous silicon dioxide. Light anhydrous silicic acid and hydrous silicon dioxide are preferred.
- a disintegrating agent for example, a disintegrating agent, a binder, a lubricant agent, an excipient
- these additives may be used singly or in combination of two or more unless otherwise specified, and the blending amount is not particularly limited, and the effect is sufficiently manifested according to each purpose. As appropriate, it may be blended appropriately.
- disintegrant examples include, but are not limited to, cellulose derivatives such as carmellose calcium, carmellose, low-substituted hydroxypropylcellulose, and croscarmellose sodium; starch derivatives such as sodium carboxymethyl starch and partially pregelatinized starch; and cloth Examples thereof include polyvinylpyrrolidone derivatives such as povidone, carmellose calcium, low-substituted hydroxypropyl cellulose, partially pregelatinized starch and carmellose are preferred, and carmellose calcium is more preferred.
- a disintegrating agent can be mix
- the content of the disintegrant can be 1 to 20% of the tablet mass, preferably 3 to 15%, more preferably 5 to 10%.
- binder examples include, but are not limited to, hydroxypropyl cellulose, polyvinyl alcohol, povidone, hypromellose, carmellose sodium, methyl cellulose, gum arabic, and dextrin, and hydroxypropyl cellulose and polyvinyl alcohol are preferable.
- the content of the binder can be 1 to 20% of the tablet mass, and preferably 2.5 to 10%.
- the lubricant is not particularly limited, and examples thereof include magnesium stearate, calcium stearate, stearic acid, sodium stearyl fumarate, talc and sucrose fatty acid ester. Magnesium stearate and sodium stearyl fumarate are preferable, Magnesium acid is more preferable.
- the content of the lubricant can be 0.1 to 5% of the tablet mass, preferably 0.2 to 5%, and more preferably 0.5 to 3%.
- excipients include, but are not limited to, sugar alcohols such as erythritol, mannitol, xylitol, and sorbitol; sugars such as sucrose, powdered sugar, lactose, and glucose; ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ - Cyclodextrins such as cyclodextrin, hydroxypropyl- ⁇ -cyclodextrin and sulfobutyl ether- ⁇ -cyclodextrin sodium; celluloses such as crystalline cellulose and microcrystalline cellulose; and starches such as corn starch, potato starch and partially pregelatinized starch Mannitol, lactose, corn starch and partially pregelatinized starch are preferred, and lactose and corn starch are more preferred.
- sugar alcohols such as erythritol, mannitol, xylitol, and sorbitol
- sugars such as suc
- the flavoring agent is not particularly limited, and examples thereof include aspartame, saccharin, stevia, thaumatin, and acesulfame potassium.
- the colorant is not particularly limited, and examples thereof include titanium dioxide, iron sesquioxide, yellow iron sesquioxide, black iron oxide, edible red No. 102, edible yellow No. 4, and edible yellow No. 5.
- the flavoring agent is not particularly limited, but for example, essential oils such as orange oil, lemon oil, mint oil and pine oil; essences such as orange essence and peppermint essence; flavors such as cherry flavor, vanilla flavor and fruit flavor; apple And powdered flavors such as micron, banana micron, peach micron, strawberry micron and orange micron; vanillin; and ethyl vanillin.
- the acid is not particularly limited, and examples thereof include hydroxycarboxylic acid, and citric acid, tartaric acid and malic acid are preferable.
- the surfactant is not particularly limited, and examples thereof include sodium lauryl sulfate, dioctyl sodium sulfosuccinate, polysorbates, and polyoxyethylene hydrogenated castor oil.
- the plasticizer is not particularly limited, and examples thereof include triethyl citrate, macrogol, triacetin, and propylene glycol.
- the surface of the tablet of the present invention may be film-coated with a coating agent as necessary.
- the coating agent examples include, but are not limited to, hypromellose, aminoalkyl methacrylate copolymer E, aminoalkyl methacrylate copolymer RS, ethyl cellulose, cellulose acetate phthalate, hypromellose phthalate, methacrylic acid copolymer L, methacrylic acid copolymer LD and Examples include methacrylic acid copolymer S, polyvinyl alcohol, hydroxypropyl methylcellulose acetate succinate, polyvinyl alcohol / acrylic acid / methyl methacrylate copolymer, and polyvinyl alcohol / polyethylene glycol / graft copolymer. Hypromellose and polyvinyl alcohol are preferred, and hypromellose is more preferred. preferable.
- Examples of the salt of Compound A according to the present invention include a salt in a basic group or acidic group that is generally known.
- Examples of basic group salts include salts with mineral acids such as hydrochloric acid, hydrogen bromide, phosphoric acid and sulfuric acid; tartaric acid, formic acid, acetic acid, fumaric acid, maleic acid, citric acid, trichloroacetic acid and trifluoroacetic acid.
- salts with organic carboxylic acids and salts with sulfonic acids such as methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, mesitylenesulfonic acid and naphthalenesulfonic acid.
- salts of an acidic group include salts with alkali metals such as sodium and potassium; salts with alkaline earth metals such as calcium and magnesium; ammonium salts and trimethylamine, triethylamine, tributylamine, trometamol, pyridine, N, N Salts with nitrogenous organic bases such as dimethylaniline, N-methylpiperidine, N-methylmorpholine, diethylamine, dicyclohexylamine, procaine, dibenzylamine, N-benzyl- ⁇ -phenethylamine and N, N′-dibenzylethylenediamine And so on.
- preferred salts of Compound A include pharmacologically acceptable salts.
- hydrate of Compound A or a salt thereof according to the present invention a hydrate of Compound A produced by the method described in JP-A-58-24569, described in International Publication No. 2009/035168 pamphlet.
- examples thereof include hydrates of compound A produced by the method or hydrates of compound A produced by the method described in Production Example 1 to be described later. Hydrates are preferred.
- the administration method, the dosage and the number of administration can be appropriately selected according to the age, weight and symptoms of the patient, but usually the amount capable of exerting the drug effect is several times a day.
- the compound A may be administered in divided doses, and usually 10 to 5000 mg, preferably 200 to 2500 mg, of Compound A may be administered to adults daily in 1 to several divided doses.
- a granulated powder is produced by a dry or wet granulation method, and if desired, an excipient, a disintegrant and / or a lubricant are further added to obtain a mixed powder for tableting. And a method of tableting.
- a wet granulation method is preferable as a method for producing the granulated powder.
- the wet granulation method is not particularly limited.
- fluidized bed granulation method, centrifugal tumbling granulation method, mixed stirring granulation method, high speed mixing stirring granulation method, rolling granulation method, wet crushing granulation Method and extrusion granulation method fluidized bed granulation method, centrifugal tumbling granulation method, mixed stirring granulation method, high speed mixed stirring granulation method, rolling granulation method and wet crushing granulation method are preferable,
- a fluidized bed granulation method is particularly preferred.
- a method of adding the binder during granulation (1) a method in which compound A or a salt thereof or a hydrate thereof is mixed and sprayed with a binder dissolved in water, (2) compound A or a salt thereof Alternatively, a method of adding a binder to the mixed powder containing the hydrate and spraying water can be used.
- the method for adding silicon dioxide (1) a method of adding powdered silicon dioxide to a mixed powder containing Compound A or a salt thereof or a hydrate thereof, and (2) a compound A or a salt thereof or a hydrate thereof.
- the tablet of the present invention is preferably a round tablet.
- the size of the round tablet may be 5 to 9 mm in diameter and 2 to 5 mm in thickness, and preferably 7 to 9 mm in diameter and 3 to 5 mm in thickness.
- the tablet of the present invention was agitated for 15 minutes in a dissolution test using the 16th revised Japanese Pharmacopoeia Dissolution Test Method (Paddle Method) with the second solution of the Japanese Pharmacopoeia Dissolution Test as the test solution and a rotation speed of 50 times / minute.
- the elution rate of the compound A afterwards is preferably 80% or more, and more preferably 85% or more.
- the hardness is preferably 30 to 150 N, and more preferably 50 to 130 N.
- a tablet hardness meter 8M manufactured by Schleunigel
- portable checker PC30 manufactured by Okada Seiko
- the dissolution test was conducted by the Japanese Pharmacopoeia dissolution test paddle method. The rotation speed of the paddle was 50 rpm. A sample was put into 900 mL of the second solution of the Japanese Pharmacopoeia dissolution test, and the test solution after stirring for 15 minutes was collected, and the dissolution rate (%) of Compound A was determined by the absorbance method.
- Test example 1 As samples, the tablets of Examples 1 to 3 and Comparative Example 1 were used. Table 1 shows the results of measurement of tablet hardness and dissolution test.
- Tablets containing light anhydrous silicic acid (Examples 1 to 3) showed remarkably superior dissolution properties compared to tablets (Comparative Example 1) produced by a conventional technique (Japanese Patent Publication No. 1-337376). Further, the tablets of Examples 1 to 3 had sufficient hardness.
- Test example 2 As samples, the tablets of Examples 4 to 6 and Comparative Example 2 were used. In the same manner as in Test Example 1, tablet hardness measurement and dissolution test were performed. The results are shown in Table 2.
- Tablets containing 3 to 0.3% light anhydrous silicic acid showed excellent dissolution properties compared with tablets not containing light anhydrous silicic acid (Comparative Example 2).
- a tablet containing 3% of light anhydrous silicic acid (Example 4) showed extremely excellent dissolution properties.
- the tablets of Examples 4 to 6 had sufficient hardness.
- Test example 3 As a sample, a tablet (Example 7) to which light silicic acid was added after granulation and a tablet (Example 8) to which light silicic acid was added before granulation were used. In the same manner as in Test Example 1, tablet hardness measurement and dissolution test were performed. The results are shown in Table 3.
- Example 7 The tablets to which light anhydrous silicic acid was added after granulation (Example 7) and the tablets added before granulation (Example 8) showed excellent dissolution properties.
- Test example 4 The uncoated tablets and film-coated tablets of Examples 9 and 10 were used as samples. In the same manner as in Test Example 1, the hardness of the uncoated tablet and the dissolution test of the film-coated tablet were performed. The results are shown in Table 4.
- Test Example 5 The film-coated tablet of Example 11 was used as a sample. In the same manner as in Test Example 1, the hardness of the uncoated tablet and the dissolution test of the film-coated tablet were performed. The results are shown in Table 5.
- Example 11 The film-coated tablet containing hydrous silicon dioxide (Example 11) showed excellent dissolution properties. Moreover, the uncoated tablet of Example 11 had sufficient hardness.
- Test Example 6 The uncoated tablets of Example 13 and Comparative Example 3 were used as samples. In the same manner as in Test Example 1, the hardness of the uncoated tablet and the dissolution test of the uncoated tablet were performed. The results are shown in Table 6.
- Example 13 The tablet containing 3% of light anhydrous silicic acid (Example 13) showed excellent dissolution properties compared with the tablet not containing light anhydrous silicic acid (Comparative Example 3). Moreover, the tablet of Example 13 had sufficient hardness.
- the reaction mixture is cooled to 5 ° C., and the crystals are collected by filtration, washed with a mixture of 20 mL of acetone and 40 mL of water, and then washed with 60 mL of acetone to give 5-hydroxy-1H-imidazole-4-carboxamide as pale yellow crystals. 12.8 g of 3/4 hydrate was obtained.
- Example 1 4.5 g of Compound A hydrate and 0.5 g of carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) were mixed in a mortar.
- binding solution ⁇ 8.7% hydroxypropylcellulose (HPC-L, manufactured by Nippon Soda), 8.7% anhydrous citric acid (manufactured by Komatsuya Co., Ltd.) and 4.3% light anhydrous silicic acid (Aerosil-200, manufactured by Aerosil Japan)
- Aqueous suspension ⁇ of 2.5 g was added and granulated.
- the obtained granulated powder is dried at 40 ° C.
- Example 2 Compound A hydrate 6g, carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) 0.3g, lactose hydrate (Pharmatose 200M, DMV-Fonterra Excipients) 0.3g and corn starch (manufactured by Nippon Shokuhin Kako) 0.39g Were mixed in a mortar. Add 3 g of binding solution ⁇ 10% polyvinyl alcohol (GOHSENOL EG-05, manufactured by Nippon Synthetic Chemical) and 5% light silicic anhydride (Aerosil-200, manufactured by Nippon Aerosil) ⁇ to this mixed powder. Grained.
- ECG-505 manufactured by Nichirin Chemical Industries
- lactose hydrate Pharmatose 200M, DMV-Fonterra Excipients
- corn starch manufactured by Nippon Shokuhin Kako
- the resulting granulated powder is dried overnight at 40 ° C, passed through a sieve with an opening of 500 ⁇ m, added with 0.8% magnesium stearate (Merck) equivalent to the tablet weight, mixed, and compression molded. Tableting was performed at a tableting pressure of 6 kN using a property measuring apparatus (TAB FLEX, manufactured by Okada Seiko Co., Ltd.) to obtain 250 mg tablets per tablet.
- TAB FLEX manufactured by Okada Seiko Co., Ltd.
- Example 3 Compound A hydrate 6g, carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) 0.3g, lactose hydrate (Pharmatose 200M, DMV-Fonterra Excipients) 0.225g, corn starch (manufactured by Nippon Shokuhin Kako) 0.315g And 0.15 g of anhydrous citric acid (manufactured by Komatsuya Co., Ltd.) was mixed in a mortar. Add 3 g of binding solution ⁇ 10% polyvinyl alcohol (GOHSENOL EG-05, manufactured by Nippon Synthetic Chemical) and 5% light silicic anhydride (Aerosil-200, manufactured by Nippon Aerosil) ⁇ to this mixed powder.
- ECG-505 manufactured by Nichirin Chemical Industries
- lactose hydrate Pharmatose 200M, DMV-Fonterra Excipients
- corn starch manufactured by Nippon Shokuhin Kako
- anhydrous citric acid
- the resulting granulated powder is dried overnight at 40 ° C, passed through a sieve with an opening of 500 ⁇ m, added with 0.8% magnesium stearate (Merck) equivalent to the tablet weight, mixed, and compression molded. Tableting was performed at a tableting pressure of 6 kN using a property measuring apparatus (TAB FLEX, manufactured by Okada Seiko Co., Ltd.) to obtain 250 mg tablets per tablet.
- TAB FLEX manufactured by Okada Seiko Co., Ltd.
- Example 4 Fluidized bed granulator and dryer (9.957 g of compound A hydrate, 0.585 g of carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) and 0.398 g of lactose hydrate (Pharmatose 200M, manufactured by DMV-Fonterra Excipients) A small amount of fluidized bed, manufactured by Fuji Powder Co., Ltd.). This mixed powder is sprayed with 7.02 g of a binding solution ⁇ 5% hydroxypropylcellulose (HPC-L, manufactured by Nippon Soda) and 5% light anhydrous silicic acid (Aerosil-200, manufactured by Nippon Aerosil) ⁇ . After granulation, it was dried.
- HPC-L hydroxypropylcellulose
- Alerosil-200 manufactured by Nippon Aerosil
- magnesium stearate 0.5% is added to the resulting granulated powder, mixed, mixed, and compressed using a compression moldability measuring device (TAB FLEX, Okada Seiko). Tableting was performed at a pressure of 10 kN to obtain 260 mg tablets per tablet.
- Example 5 Fluidized bed granulator and dryer (9.957 g of compound A, carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) 0.585 g and lactose hydrate (Pharmatose 200M, manufactured by DMV-Fonterra Excipients) 0.632 g A small amount of fluidized bed, manufactured by Fuji Powder Co., Ltd.).
- This mixed powder is sprayed with 7.02 g of a binding solution ⁇ 5% hydroxypropylcellulose (HPC-L, Nippon Soda) and 1.5% light anhydrous silicic acid (Aerosil-200, Nippon Aerosil) aqueous suspension ⁇ . After granulation, it was dried.
- magnesium stearate 0.5% is added to the resulting granulated powder, mixed, mixed, and compressed using a compression moldability measuring device (TAB FLEX, Okada Seiko). Tableting was performed at a pressure of 10 kN to obtain 260 mg tablets per tablet.
- Example 6 Fluidized bed granulator / dryer of 9.957 g of Compound A hydrate, 0.585 g of carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) and 0.714 g of lactose hydrate (Pharmatose 200M, manufactured by DMV-Fonterra Excipients) A small amount of fluidized bed, manufactured by Fuji Powder Co., Ltd.).
- This mixed powder is sprayed with 7.02 g of a binding solution ⁇ 5% hydroxypropylcellulose (HPC-L, Nippon Soda) and 0.5% light anhydrous silicic acid (Aerosil-200, Nippon Aerosil) ⁇ . After granulation, it was dried.
- magnesium stearate 0.5% is added to the resulting granulated powder, mixed, mixed, and compressed using a compression moldability measuring device (TAB FLEX, Okada Seiko). Tableting was performed at a pressure of 10 kN to obtain 260 mg tablets per tablet.
- Example 7 Fluidized bed granulator and dryer (9.957 g of compound A hydrate, 0.585 g of carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) and 0.398 g of lactose hydrate (Pharmatose 200M, manufactured by DMV-Fonterra Excipients) A small amount of fluidized bed, manufactured by Fuji Powder Co., Ltd.). This mixed powder was sprayed and granulated with 7.02 g of a binding solution ⁇ 5% hydroxypropylcellulose (HPC-L, manufactured by Nippon Soda Co., Ltd.) ⁇ and dried.
- HPC-L a binding solution ⁇ 5% hydroxypropylcellulose
- Example 8 9.957 g of Compound A hydrate, 0.585 g of carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries), 0.398 g of lactose hydrate (Pharmatose 200M, manufactured by DMV-Fonterra Excipients) and light anhydrous silicic acid (Aerosil-200) , Nippon Aerosil Co., Ltd.) (0.351 g) was mixed using a fluidized bed granulator / dryer (a small amount of fluidized bed, manufactured by Fuji Powder).
- This mixed powder was sprayed and granulated with 7.02 g of a binding solution ⁇ 5% hydroxypropylcellulose (HPC-L, manufactured by Nippon Soda Co., Ltd.) ⁇ and dried. 0.5% of magnesium stearate (Merck) is added to the resulting granulated powder, mixed, mixed, and compressed using a compression moldability measuring device (TAB FLEX, Okada Seiko). Tableting was performed at a pressure of 6 kN to obtain 260 mg tablets per tablet.
- HPC-L hydroxypropylcellulose
- TAB FLEX Okada Seiko
- Example 9 442.52 g of Compound A hydrate pulverized by a pin mill (ALPINE fine pulverizer 630, manufactured by Paulek), 44.8 g of carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) and lactose hydrate (Pharmatose 200M, 27.88 g (manufactured by DMV-Fonterra Excipients) was mixed with a fluidized bed granulator / dryer (FD-MP-01, manufactured by Paulek).
- ALPINE fine pulverizer 630 manufactured by Paulek
- ECG-505 carmellose calcium
- lactose hydrate Pharmatose 200M, 27.88 g (manufactured by DMV-Fonterra Excipients) was mixed with a fluidized bed granulator / dryer (FD-MP-01, manufactured by Paulek).
- This mixed powder is granulated by spraying 336 g of a binding solution ⁇ 5% hydroxypropylcellulose (HPC-L, manufactured by Nippon Soda) and 5% light anhydrous silicic acid (Aerosil-200, manufactured by Nippon Aerosil) ⁇ And then dried.
- 2% of magnesium stearate (Merck) is added to the resulting granulated powder, mixed, and mixed using a rotary tableting machine (HT-P18A, Hata Tekko). Tableting was performed at a tablet pressure of 10 kN to obtain 280 mg of uncoated tablets per tablet.
- Example 10 Compound A hydrate 110.64 g, Carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) 22.4 g and lactose hydrate (Pharmatose 200M, pulverized with a pin mill pulverizer (ALPINE fine pulverizer 630, manufactured by Paulek) 124.56 g (manufactured by DMV-Fonterra Excipients) was mixed using a fluidized bed granulator / dryer (FD-MP-01, manufactured by Paulek).
- FD-MP-01 fluidized bed granulator / dryer
- This mixed powder is granulated by spraying 168 g of binding liquid ⁇ 5% hydroxypropylcellulose (HPC-L, Nippon Soda) and 5% light anhydrous silicic acid (Aerosil-200, Nippon Aerosil) aqueous suspension ⁇ . And then dried. 2% of magnesium stearate (Merck) is added to the resulting granulated powder, mixed, and mixed using a rotary tableting machine (HT-P18A, Hata Tekko). Tableting was performed at a tablet pressure of 3 kN to obtain 70 mg round (5.5 mm SR) plain tablets per tablet.
- HPC-L hydroxypropylcellulose
- Al-200 5% light anhydrous silicic acid
- 2% of magnesium stearate (Merck) is added to the resulting granulated powder, mixed, and mixed using a rotary tableting machine (HT-P18A, Hata Tekko). Tableting was performed at a tablet pressure of 3 kN to obtain 70 mg round
- Example 11 Compound A hydrate 221.26g, carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) 22.4g and lactose hydrate (Pharmatose 200M, pulverized with a pin mill pulverizer (ALPINE fine pulverizer 630, manufactured by Paulek) DMV-Fonterra Excipients) (13.94 g) was mixed using a fluidized bed granulator / dryer (FD-MP-01, manufactured by Paulek). This mixed powder was granulated by spraying 168 g of a binding solution ⁇ 5% hydroxypropylcellulose (HPC-L, manufactured by Nippon Soda) and 5% hydrous silicon dioxide (Carplex 80, manufactured by Freund Sangyo) ⁇ .
- HPC-L hydroxypropylcellulose
- Carplex 80 manufactured by Freund Sangyo
- Example 12 Compound A hydrate 221.26g pulverized with a pin mill pulverizer (ALPINE fine pulverizer 630, Paulek), lactose hydrate (Pharmatose 200M, DMV-Fonterra Excipients) 13.94g and carmellose calcium (ECG- 22.4 g (505, manufactured by Nichirin Chemical Industry Co., Ltd.) was mixed using a fluidized bed granulator / dryer (FD-MP-01, manufactured by Paulek).
- ALPINE fine pulverizer 630 pin mill pulverizer 630, Paulek
- lactose hydrate Pharmatose 200M, DMV-Fonterra Excipients
- ECG- 22.4 g 505, manufactured by Nichirin Chemical Industry Co., Ltd.
- FD-MP-01 fluidized bed granulator / dryer
- This mixed powder is granulated by spraying 168 g of binding liquid ⁇ 5% hydroxypropylcellulose (HPC-L, Nippon Soda) and 5% light anhydrous silicic acid (Aerosil-200, Nippon Aerosil) aqueous suspension ⁇ . And then dried. 2% of magnesium stearate (Merck) is added to the resulting granulated powder, mixed, and mixed using a rotary tableting machine (HT-P18A, Hata Tekko). Tableting was performed at a tablet pressure of 10 kN to obtain 280 mg of uncoated tablets per tablet.
- HPC-L hydroxypropylcellulose
- Al-200 5% light anhydrous silicic acid
- 2% of magnesium stearate (Merck) is added to the resulting granulated powder, mixed, and mixed using a rotary tableting machine (HT-P18A, Hata Tekko). Tableting was performed at a tablet pressure of 10 kN to obtain 280 mg of uncoated
- the coating agent per uncoated tablet ⁇ Opadry 03A470001 TAN (hypromellose 2910: 60.00%, talc: 20.00%, titanium oxide: 18.86%, yellow ferric oxide: 1.00% , Black iron oxide: 0.14%, manufactured by Nippon Colorcon) ⁇ 10mg coated, and then polished with Carnauba wax (Polishing Wax-105, manufactured by Nippon Wax) equivalent to 0.015% of the weight of the tablet obtained, Film-coated tablets were obtained. Table 7 shows the composition of the film-coated tablet.
- Example 13 11.06 g of Compound A hydrate, 0.700 g of low-substituted hydroxypropylcellulose (L-HPC LH-11, Shin-Etsu Chemical Co., Ltd.) and 1.117 g of lactose hydrate (Pharmatose 200M, manufactured by DMV-Fonterra Excipients) were mixed in a mortar. . To this mixed powder is added 5.444 g of a binding solution ⁇ 7.7% hydroxypropylcellulose (HPC-L, manufactured by Nippon Soda), and 7.7% light anhydrous silicic acid (Aerosil-200, manufactured by Nippon Aerosil) ⁇ Granulated. The obtained granulated powder is dried at 40 ° C.
- Comparative Example 1 Tablets were produced according to the method described in JP-B-1-37376. Specifically, Compound A hydrate 6g, carmellose calcium (ECG-505, manufactured by Nichirin Chemical Industries) 0.3g, lactose hydrate (Pharmatose 200M, manufactured by DMV-Fonterra Excipients) 0.375g and corn starch (Japanese food) 0.465 g (Kako) was mixed in a mortar. To this mixed powder, 3 g of a binding solution ⁇ 10% aqueous solution of polyvinyl alcohol (Gosenol EG-05, manufactured by Nippon Synthetic Chemical) ⁇ was added and granulated.
- the resulting granulated powder is dried overnight at 40 ° C, passed through a sieve with an opening of 500 ⁇ m, added with 0.8% magnesium stearate (Merck) equivalent to the tablet weight, mixed, and compression molded. Tableting was performed at a tableting pressure of 6 kN using a property measuring apparatus (TAB FLEX, manufactured by Okada Seiko Co., Ltd.) to obtain 250 mg tablets per tablet.
- TAB FLEX manufactured by Okada Seiko Co., Ltd.
- magnesium stearate 0.5% is added to the resulting granulated powder, mixed, mixed, and compressed using a compression moldability measuring device (TAB FLEX, Okada Seiko). Tableting was performed at a pressure of 10 kN to obtain 260 mg tablets per tablet.
- Comparative Example 3 11.06 g of Compound A hydrate, 0.700 g of low-substituted hydroxypropyl cellulose (L-HPC LH-11, Shin-Etsu Chemical Co., Ltd.) and 1.537 g of lactose hydrate (Pharmatose 200M, DMV-Fonterra Excipients) were mixed in a mortar. . To this mixed powder, 5.444 g of a binding solution ⁇ aqueous suspension of 7.7% hydroxypropylcellulose (HPC-L, Nippon Soda) ⁇ was added and granulated. The obtained granulated powder is dried at 40 ° C.
- the tablet of the present invention is useful as a tablet having a high content of compound A or a salt thereof or a hydrate thereof, a tablet size that is easy to take, and an excellent dissolution property.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
[1](1)5-ヒドロキシ-1H-イミダゾール-4-カルボキサミドもしくはその塩またはその水和物および(2)二酸化ケイ素を含有する錠剤。
[2]さらに添加剤を含む[1]に記載の錠剤。
[3]添加剤が崩壊剤を含む添加剤である[2]に記載の錠剤。
[4]二酸化ケイ素がシリカゲル、無水ケイ酸、コロイド状二酸化ケイ素、軽質無水ケイ酸および含水二酸化ケイ素から選ばれる1種または2種以上である[1]~[3]のいずれか一つに記載の錠剤。
[5]二酸化ケイ素が軽質無水ケイ酸および含水二酸化ケイ素からから選ばれる1種または2種である[1]~[3]のいずれか一つに記載の錠剤。
[6]二酸化ケイ素の含有率が、錠剤質量の0.1~20%である[1]~[5]のいずれか一つに記載の錠剤。
[7]崩壊剤がセルロース誘導体、デンプン誘導体およびポリビニルピロリドン誘導体から選ばれる1種または2種以上である[3]に記載の錠剤。
[8]崩壊剤がカルメロースカルシウム、カルメロース、低置換度ヒドロキシプロピルセルロース、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、部分アルファー化デンプンおよびクロスポビドンから選ばれる1種または2種以上である[3]に記載の錠剤。
[9]崩壊剤がカルメロースカルシウム、低置換度ヒドロキシプロピルセルロースおよび部分アルファー化デンプンから選ばれる1種または2種以上である[3]に記載の錠剤。
[10]崩壊剤がカルメロースカルシウムである[3]に記載の錠剤。
[11]5-ヒドロキシ-1H-イミダゾール-4-カルボキサミドもしくはその塩またはその水和物の含有率が、錠剤質量の0.3~95%である[1]~[10]のいずれか一つに記載の錠剤。
[12]湿式造粒法により製造した造粒末を使用して錠剤化される、[1]~[11]のいずれか一つに記載の錠剤の製造方法。
[13]湿式造粒法が流動層造粒法である[12]に記載の製造方法。
[15]さらに添加剤を含有する造粒末を打錠して得られる[14]に記載の錠剤。
[16]添加剤が崩壊剤を含む添加剤である[14]に記載の錠剤。
[17]二酸化ケイ素がシリカゲル、無水ケイ酸、コロイド状二酸化ケイ素、軽質無水ケイ酸および含水二酸化ケイ素から選ばれる1種または2種以上である[14]~[16]のいずれか一つに記載の錠剤。
[18]二酸化ケイ素が軽質無水ケイ酸および含水二酸化ケイ素からから選ばれる1種または2種である[14]~[16]のいずれか一つに記載の錠剤。
[19]二酸化ケイ素の含有率が、錠剤質量の0.1~20%である[14]~[18]のいずれか一つに記載の錠剤。
[20]崩壊剤がセルロース誘導体、デンプン誘導体およびポリビニルピロリドン誘導体から選ばれる1種または2種以上である[16]に記載の錠剤。
[21]崩壊剤がカルメロースカルシウム、カルメロース、低置換度ヒドロキシプロピルセルロース、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、部分アルファー化デンプンおよびクロスポビドンから選ばれる1種または2種以上である[16]に記載の錠剤。
[22]崩壊剤がカルメロースカルシウム、低置換度ヒドロキシプロピルセルロースおよび部分アルファー化デンプンから選ばれる1種または2種以上である[16]に記載の錠剤。
[23]崩壊剤がカルメロースカルシウムである[16]に記載の錠剤。
[24]5-ヒドロキシ-1H-イミダゾール-4-カルボキサミドもしくはその塩またはその水和物の含有率が、錠剤質量の0.3~95%である[14]~[23]のいずれか一つに記載の錠剤。
本発明に使用される%は、特に断らない限り、質量百分率を意味する。本発明において「~」を用いて示された数値範囲は、「~」の前後に記載される数値をそれぞれ最小値および最大値として含む範囲を示す。さらに本発明において組成物中の各成分の量は、組成物中に各成分に該当する物質が複数存在する場合、特に断らない限り、組成物中に存在する当該複数の物質の合計量を意味する。
化合物Aもしくはその塩またはその水和物の含有率は、錠剤質量の0.3~95%とすることができ、20~90%が好ましく、40~85%がより好ましい。
二酸化ケイ素の含有率は、錠剤質量の0.1~20%とすることができ、0.5~15%が好ましく、1~5%がより好ましい。
二酸化ケイ素の含有率は、錠剤質量の0.3~3%が好ましい。
なお、本発明で「錠剤質量」というときは、フィルムコーティング錠については、特に記載した場合を除き、コーティング前の錠剤の質量を指す。
二酸化ケイ素としては、特に限定されないが、例えば、シリカゲル、無水ケイ酸、コロイド状二酸化ケイ素、軽質無水ケイ酸および含水二酸化ケイ素が挙げられ、軽質無水ケイ酸および含水二酸化ケイ素が好ましい。
崩壊剤は、造粒末内および/または造粒末外に配合することができる。
崩壊剤の含有率は、錠剤質量の1~20%とすることができ、3~15%が好ましく、5~10%がより好ましい。
結合剤の含有率は、錠剤質量の1~20%とすることができ、2.5~10%が好ましい。
滑沢剤の含有率は、錠剤質量の0.1~5%とすることができ、0.2~5%が好ましく、0.5~3%がより好ましい。
塩基性基の塩としては、例えば、塩酸、臭化水素、リン酸および硫酸などの鉱酸との塩;酒石酸、ギ酸、酢酸、フマル酸、マレイン酸、クエン酸、トリクロロ酢酸およびトリフルオロ酢酸などの有機カルボン酸との塩ならびにメタンスルホン酸、ベンゼンスルホン酸、p-トルエンスルホン酸、メシチレンスルホン酸およびナフタレンスルホン酸などのスルホン酸との塩などが挙げられる。
酸性基の塩としては、例えば、ナトリウムおよびカリウムなどのアルカリ金属との塩;カルシウムおよびマグネシウムなどのアルカリ土類金属との塩;アンモニウム塩ならびにトリメチルアミン、トリエチルアミン、トリブチルアミン、トロメタモール、ピリジン、N,N-ジメチルアニリン、N-メチルピペリジン、N-メチルモルホリン、ジエチルアミン、ジシクロヘキシルアミン、プロカイン、ジベンジルアミン、N-ベンジル-β-フェネチルアミンおよびN,N'-ジベンジルエチレンジアミンなどの含窒素有機塩基との塩などを挙げることができる。
さらに、上記、塩の中で化合物Aの好ましい塩としては、薬理学的に許容される塩が挙げられる。
湿式造粒法としては、特に限定されないが、例えば、流動層造粒法、遠心転動造粒法、混合撹拌造粒法、高速混合撹拌造粒法、転動造粒法、湿式破砕造粒法および押出造粒法が挙げられ、流動層造粒法、遠心転動造粒法、混合撹拌造粒法、高速混合撹拌造粒法、転動造粒法および湿式破砕造粒法が好ましく、流動層造粒法が特に好ましい。
錠剤硬度の測定は、錠剤硬度計8M(シュロイニゲル製)またはポータブルチェッカーPC30(岡田精工製)を使用した。
溶出試験は、日本薬局方溶出試験パドル法によって行った。パドルの回転数は、50rpmとした。日本薬局方溶出試験第2液900mLに試料を投入し、15分間撹拌した後の試験液を採取し、化合物Aの溶出率(%)を吸光度法により求めた。
試料として、実施例1~3および比較例1の錠剤を使用した。
錠剤硬度の測定および溶出試験の結果を表1に示す。
試料として、実施例4~6および比較例2の錠剤を使用した。
試験例1と同様にして、錠剤硬度の測定および溶出試験を行った。結果を表2に示す。
試料として、造粒後に軽質無水ケイ酸を添加した錠剤(実施例7)および造粒前に軽質無水ケイ酸を添加した錠剤(実施例8)を使用した。
試験例1と同様にして、錠剤硬度の測定および溶出試験を行った。結果を表3に示す。
試料として、実施例9および10の素錠およびフィルムコーティング錠を使用した。
試験例1と同様にして、素錠の硬度の測定およびフィルムコーティング錠の溶出試験を行った。結果を表4に示す。
試料として、実施例11のフィルムコーティング錠を使用した。
試験例1と同様にして、素錠の硬度の測定およびフィルムコーティング錠の溶出試験を行った。結果を表5に示す。
試料として、実施例13および比較例3の素錠を使用した。
試験例1と同様にして、素錠の硬度の測定および素錠の溶出試験を行った。結果を表6に示す。
また、実施例13の錠剤は、十分な硬度を有していた。
化合物Aの水和物は、製造例1に記載の方法に準じて製造した化合物Aの3/4水和物を使用した。
コーティング剤は、特にことわらない限り、オパドライ03A48081(ヒプロメロース2910:酸化チタン:タルク=60:20:20、日本カラコン社製)を使用した。
各実施例および比較例の錠剤形状は、特にことわらない限り、円形(8.5mmDR)とした。
(1)窒素雰囲気下、2-プロパノール600mLに2-アミノマロンアミド(立山化成)30gおよびシュウ酸115mgを加え、82℃に加熱した後、オルトギ酸トリエチル(日宝化学、純度:99.5%)106mLを10分かけて滴下した。次いで、反応混合物を84℃で7時間30分間撹拌した。57℃まで冷却後、反応混合物に水30mLおよび濃塩酸24mLを順次添加した。反応混合物を5℃まで冷却し、結晶を濾取し、アセトン120mLで洗浄し、淡黄色結晶の5-ヒドロキシ-1H-イミダゾール-4-カルボキサミド塩酸塩二水和物49gを得た。
(2)窒素雰囲気下、0.45mol/L塩酸240mLに5-ヒドロキシ-1H-イミダゾール-4-カルボキサミド塩酸塩二水和物20.0gを加え、50℃に加熱して溶解させた。この溶液にギ酸ナトリウム14.3gの水40mL溶液を33分かけて滴下した。反応混合物を5℃まで冷却し、結晶を濾取し、アセトン20mLおよび水40mLの混合液で洗浄し、次いでアセトン60mLで洗浄し、淡黄色結晶として5-ヒドロキシ-1H-イミダゾール-4-カルボキサミド・3/4水和物12.8gを得た。
化合物Aの水和物4.5gおよびカルメロースカルシウム(ECG-505、ニチリン化学工業製)0.5gを乳鉢で混合した。この混合末に結合液{8.7%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)、8.7%無水クエン酸(小松屋株式会社製)および4.3%軽質無水ケイ酸(アエロジル-200、日本アエロジル製)の水性懸濁液}2.5gを添加し、造粒した。得られた造粒末を40℃で2時間乾燥した後、目開き500μmの篩を通し、錠剤重量に対し、0.5%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、圧縮成形性測定装置(TAB FLEX、岡田精工製)を用いて打錠圧6kNで打錠し、1錠あたり300mgの錠剤を得た。
化合物Aの水和物6g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)0.3g、乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)0.3gおよびコーンスターチ(日本食品化工製)0.39gを乳鉢で混合した。この混合末に結合液{10%ポリビニルアルコール(ゴーセノールEG-05、日本合成化学製)および5%軽質無水ケイ酸(アエロジル-200、日本アエロジル製)の水性懸濁液}3gを添加し、造粒した。得られた造粒末を40℃で一夜乾燥した後、目開き500μmの篩を通し、錠剤重量に対し、0.8%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、圧縮成形性測定装置(TAB FLEX、岡田精工製)を用いて打錠圧6kNで打錠し、1錠あたり250mgの錠剤を得た。
化合物Aの水和物6g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)0.3g、乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)0.225g、コーンスターチ(日本食品化工製)0.315gおよび無水クエン酸(小松屋株式会社製)0.15gを乳鉢で混合した。この混合末に結合液{10%ポリビニルアルコール(ゴーセノールEG-05、日本合成化学製)および5%軽質無水ケイ酸(アエロジル-200、日本アエロジル製)の水性懸濁液}3gを添加し、造粒した。得られた造粒末を40℃で一夜乾燥した後、目開き500μmの篩を通し、錠剤重量に対し、0.8%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、圧縮成形性測定装置(TAB FLEX、岡田精工製)を用いて打錠圧6kNで打錠し、1錠あたり250mgの錠剤を得た。
化合物Aの水和物9.957g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)0.585gおよび乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)0.398gを流動層造粒乾燥機(微少量流動層、不二パウダル製)で混合した。この混合末に結合液{5%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)および5%軽質無水ケイ酸(アエロジル-200、日本アエロジル製)の水性懸濁液}7.02gを噴霧して造粒した後、乾燥した。得られた造粒末に錠剤重量に対し、0.5%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、圧縮成形性測定装置(TAB FLEX、岡田精工製)を用いて打錠圧10kNで打錠し、1錠あたり260mgの錠剤を得た。
化合物Aの水和物9.957g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)0.585gおよび乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)0.632gを流動層造粒乾燥機(微少量流動層、不二パウダル製)で混合した。この混合末に結合液{5%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)および1.5%軽質無水ケイ酸(アエロジル-200、日本アエロジル製)の水性懸濁液}7.02gを噴霧して造粒した後、乾燥した。得られた造粒末に錠剤重量に対し、0.5%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、圧縮成形性測定装置(TAB FLEX、岡田精工製)を用いて打錠圧10kNで打錠し、1錠あたり260mgの錠剤を得た。
化合物Aの水和物9.957g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)0.585gおよび乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)0.714gを流動層造粒乾燥機(微少量流動層、不二パウダル製)で混合した。この混合末に結合液{5%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)および0.5%軽質無水ケイ酸(アエロジル-200、日本アエロジル製)の水性懸濁液}7.02gを噴霧して造粒した後、乾燥した。得られた造粒末に錠剤重量に対し、0.5%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、圧縮成形性測定装置(TAB FLEX、岡田精工製)を用いて打錠圧10kNで打錠し、1錠あたり260mgの錠剤を得た。
化合物Aの水和物9.957g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)0.585gおよび乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)0.398gを流動層造粒乾燥機(微少量流動層、不二パウダル製)で混合した。この混合末に結合液{5%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)の水溶液}7.02gを噴霧して造粒した後、乾燥した。得られた造粒末に錠剤重量に対し、3%相当量の軽質無水ケイ酸(アエロジル-200、日本アエロジル製)および0.5%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、圧縮成形性測定装置(TAB FLEX、岡田精工製)を用いて打錠圧6kNで打錠し、1錠あたり260mgの錠剤を得た。
化合物Aの水和物9.957g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)0.585 g、乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)0.398gおよび軽質無水ケイ酸(アエロジル-200、日本アエロジル製)0.351gを流動層造粒乾燥機(微少量流動層、不二パウダル製)で混合した。この混合末に結合液{5%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)の水溶液}7.02gを噴霧して造粒した後、乾燥した。得られた造粒末に錠剤重量に対し、0.5%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、圧縮成形性測定装置(TAB FLEX、岡田精工製)を用いて打錠圧6kNで打錠し、1錠あたり260mgの錠剤を得た。
ピンミル粉砕機(ALPINE微粉砕機630、パウレック製)にて粉砕した化合物Aの水和物442.52g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)44.8gおよび乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)27.88gを流動層造粒乾燥機(FD-MP-01、パウレック製)で混合した。この混合末に結合液{5%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)および5%軽質無水ケイ酸(アエロジル-200、日本アエロジル製)の水性懸濁液}336gを噴霧して造粒した後、乾燥した。得られた造粒末に素錠重量に対し、2%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、ロータリー打錠機(HT-P18A、畑鉄工製)を用いて打錠圧10kNで打錠し、1錠あたり280mgの素錠を得た。コーティング機(DRC-200、パウレック製)を用いて素錠1錠あたりにコーティング剤12mgをコーティングした後、素錠重量に対し、0.015%相当量のカルナウバロウ(ポリシングワックス-105、日本ワックス製)により艶出しを行い、フィルムコーティング錠を得た。
ピンミル粉砕機(ALPINE微粉砕機630、パウレック製)にて粉砕した化合物Aの水和物110.64g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)22.4gおよび乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)124.56gを流動層造粒乾燥機(FD-MP-01、パウレック製)で混合した。この混合末に結合液{5%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)および5%軽質無水ケイ酸(アエロジル-200、日本アエロジル製)の水性懸濁液}168gを噴霧して造粒した後、乾燥した。得られた造粒末に素錠重量に対し、2%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、ロータリー打錠機(HT-P18A、畑鉄工製)を用いて打錠圧3kNで打錠し、1錠あたり70mgの円形(5.5mmSR)の素錠を得た。コーティング機(DRC-200、パウレック製)を用いて素錠1錠あたりにコーティング剤5mgをコーティングした後、素錠重量に対し、0.015%相当量のカルナウバロウ(ポリシングワックス-105、日本ワックス製)により艶出しを行い、フィルムコーティング錠を得た。
ピンミル粉砕機(ALPINE微粉砕機630、パウレック製)にて粉砕した化合物Aの水和物221.26g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)22.4gおよび乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)13.94gを流動層造粒乾燥機(FD-MP-01、パウレック製)で混合した。この混合末に結合液{5%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)および5%含水二酸化ケイ素(カープレックス 80、フロイント産業製)の水性懸濁液}168gを噴霧して造粒した後、乾燥した。得られた造粒末に素錠重量に対し、2%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、ロータリー打錠機(HT-P18A、畑鉄工製)を用いて打錠圧10kNで打錠し、1錠あたり280mgの素錠を得た。コーティング機(DRC-200、パウレック製)を用いて素錠1錠あたりにコーティング剤12mgをコーティングし、フィルムコーティング錠を得た。
ピンミル粉砕機(ALPINE微粉砕機630、パウレック製)にて粉砕した化合物Aの水和物221.26gに、乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)13.94gおよびカルメロースカルシウム(ECG-505、ニチリン化学工業製)22.4gを流動層造粒乾燥機(FD-MP-01、パウレック製)で混合した。この混合末に結合液{5%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)および5%軽質無水ケイ酸(アエロジル-200、日本アエロジル製)の水性懸濁液}168gを噴霧して造粒した後、乾燥した。得られた造粒末に素錠重量に対し、2%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、ロータリー打錠機(HT-P18A、畑鉄工製)を用いて打錠圧10kNで打錠し、1錠あたり280mgの素錠を得た。コーティング機(DRC-200、パウレック製)を用いて素錠1錠あたりにコーティング剤{オパドライ03A470001 TAN(ヒプロメロース2910:60.00%、タルク:20.00%、酸化チタン:18.86%、黄色三二酸化鉄:1.00%、黒酸化鉄:0.14%、日本カラコン製)}10mgをコーティングした後、得られた錠剤の重量に対し、0.015%相当量のカルナウバロウ(ポリシングワックス-105、日本ワックス製)により艶出しを行い、フィルムコーティング錠を得た。表7にフィルムコーティング錠の組成を示す。
化合物Aの水和物11.06gおよび低置換ヒドロキシプロピルセルロース(L-HPC LH-11、信越化学工業)0.700 gおよび乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)1.117gを乳鉢で混合した。この混合末に結合液{7.7%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)、および7.7%軽質無水ケイ酸(アエロジル-200、日本アエロジル製)の水性懸濁液}5.444gを添加し、造粒した。得られた造粒末を40℃で2時間乾燥した後、目開き500μmの篩を通し、錠剤重量に対し、2.0%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、ロータリー打錠機(HT-P18A、畑鉄工製)を用いて打錠圧8kNで打錠し、1錠あたり280mgの錠剤を得た。
特公平1-37376号公報に記載の方法に準じて錠剤を製造した。
具体的には、化合物Aの水和物6g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)0.3g、乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)0.375gおよびコーンスターチ(日本食品化工製)0.465gを乳鉢で混合した。この混合末に結合液{10%ポリビニルアルコール(ゴーセノールEG-05、日本合成化学製)の水溶液}3gを添加し、造粒した。得られた造粒末を40℃で一夜乾燥した後、目開き500μmの篩を通し、錠剤重量に対し、0.8%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、圧縮成形性測定装置(TAB FLEX、岡田精工製)を用いて打錠圧6kNで打錠し、1錠あたり250mgの錠剤を得た。
化合物Aの水和物9.957g、カルメロースカルシウム(ECG-505、ニチリン化学工業製)0.585gおよび乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)0.749gを流動層造粒乾燥機(微少量流動層、不二パウダル製)で混合した。この混合末に結合液{5%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)の水溶液}7.02gを噴霧して造粒した後、乾燥した。得られた造粒末に錠剤重量に対し、0.5%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、圧縮成形性測定装置(TAB FLEX、岡田精工製)を用いて打錠圧10kNで打錠し、1錠あたり260mgの錠剤を得た。
化合物Aの水和物11.06gおよび低置換ヒドロキシプロピルセルロース(L-HPC LH-11、信越化学工業)0.700gおよび乳糖水和物(Pharmatose 200M、DMV-Fonterra Excipients製)1.537gを乳鉢で混合した。この混合末に結合液{7.7%ヒドロキシプロピルセルロース(HPC-L、日本曹達製)の水性懸濁液}5.444gを添加し、造粒した。得られた造粒末を40℃で2時間乾燥した後、目開き500μmの篩を通し、錠剤重量に対し、2.0%相当量のステアリン酸マグネシウム(メルク製)を添加し、混合して、ロータリー打錠機(HT-P18A、畑鉄工製)を用いて打錠圧8kNで打錠し、1錠あたり280mgの錠剤を得た。
Claims (13)
- (1)5-ヒドロキシ-1H-イミダゾール-4-カルボキサミドもしくはその塩またはその水和物および(2)二酸化ケイ素を含有する錠剤。
- さらに添加剤を含む請求項1に記載の錠剤。
- 添加剤が崩壊剤を含む添加剤である請求項2に記載の錠剤。
- 二酸化ケイ素がシリカゲル、無水ケイ酸、コロイド状二酸化ケイ素、軽質無水ケイ酸および含水二酸化ケイ素から選ばれる1種または2種以上である請求項1~3のいずれか一項に記載の錠剤。
- 二酸化ケイ素が軽質無水ケイ酸および含水二酸化ケイ素からから選ばれる1種または2種以上である請求項1~3のいずれか一項に記載の錠剤。
- 二酸化ケイ素の含有率が、錠剤質量の0.1~20%である請求項1~5のいずれか一項に記載の錠剤。
- 崩壊剤がセルロース誘導体、デンプン誘導体およびポリビニルピロリドン誘導体から選ばれる1種または2種以上である請求項3に記載の錠剤。
- 崩壊剤がカルメロースカルシウム、カルメロース、低置換度ヒドロキシプロピルセルロース、クロスカルメロースナトリウム、カルボキシメチルスターチナトリウム、部分アルファー化デンプンおよびクロスポビドンから選ばれる1種または2種以上である請求項3に記載の錠剤。
- 崩壊剤がカルメロースカルシウム、低置換度ヒドロキシプロピルセルロースおよび部分アルファー化デンプンから選ばれる1種または2種以上である請求項3に記載の錠剤。
- 崩壊剤がカルメロースカルシウムである請求項3に記載の錠剤。
- 5-ヒドロキシ-1H-イミダゾール-4-カルボキサミドもしくはその塩またはその水和物の含有率が、錠剤質量の0.3~95%である請求項1~10のいずれか一項に記載の錠剤。
- 湿式造粒法により製造した造粒末を使用して錠剤化される、請求項1~11のいずれか一項に記載の錠剤の製造方法。
- 湿式造粒法が流動層造粒法である請求項12に記載の製造方法。
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
RU2014143976A RU2654703C2 (ru) | 2013-01-15 | 2014-01-15 | Таблетки, содержащие 5-гидрокси-1н-имидазол-4-карбоксамид |
ES14740552.6T ES2622568T3 (es) | 2013-01-15 | 2014-01-15 | Comprimido que contiene 5-hidroxi-1H-imidazol-4-carboxamida |
DK14740552.6T DK2946780T3 (en) | 2013-01-15 | 2014-01-15 | TABLE CONTAINING 5-HYDROXY-1H-IMIDAZOLE-4-CARBOXAMIDE |
LTEP14740552.6T LT2946780T (lt) | 2013-01-15 | 2014-01-15 | Tabletė, turinti 5-hidroksi-1h-imidazol-4-karboksamido |
SI201430172A SI2946780T1 (sl) | 2013-01-15 | 2014-01-15 | Tableta, ki vsebuje 5-hidroksi-1h-imidazol-4-karboksamid |
CN201480001101.9A CN104271134B (zh) | 2013-01-15 | 2014-01-15 | 含有5-羟基-1h-咪唑-4-甲酰胺的片剂 |
RS20170377A RS56032B1 (sr) | 2013-01-15 | 2014-01-15 | Tableta koja sadrži 5-hidroksi-1h-imidazol-4-karboksamid |
EP14740552.6A EP2946780B1 (en) | 2013-01-15 | 2014-01-15 | Tablet containing 5-hydroxy-1h-imidazole-4-carboxamide |
BR112014027231A BR112014027231A2 (pt) | 2013-01-15 | 2014-01-15 | comprimido contendo 5-hidróxi-1h-imidazola-4-carboxamida |
JP2014557486A JP5805891B2 (ja) | 2013-01-15 | 2014-01-15 | 5−ヒドロキシ−1h−イミダゾール−4−カルボキサミドを含有する錠剤 |
US14/528,768 US9248102B2 (en) | 2013-01-15 | 2014-10-30 | Tablet containing 5-hydroxy-1H-imidazole-4-carboxamide |
HK15106090.9A HK1205463A1 (zh) | 2013-01-15 | 2015-06-26 | 含有 -羥基- -咪唑- -甲酰胺的片劑 |
CY20171100434T CY1119159T1 (el) | 2013-01-15 | 2017-04-11 | Δισκιο το οποιο περιεχει 5-υδροξυ-1η-ιμιδαζολο-4-καρβοξαμιδiο |
HRP20170571TT HRP20170571T1 (hr) | 2013-01-15 | 2017-04-11 | Tableta koja sadrži 5-hidroksi-1h-imidazol-4-karboksamid |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2013-004995 | 2013-01-15 | ||
JP2013004995 | 2013-01-15 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US14/528,768 Continuation US9248102B2 (en) | 2013-01-15 | 2014-10-30 | Tablet containing 5-hydroxy-1H-imidazole-4-carboxamide |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014112530A1 true WO2014112530A1 (ja) | 2014-07-24 |
Family
ID=51209619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2014/050591 WO2014112530A1 (ja) | 2013-01-15 | 2014-01-15 | 5-ヒドロキシ-1h-イミダゾール-4-カルボキサミドを含有する錠剤 |
Country Status (17)
Country | Link |
---|---|
US (1) | US9248102B2 (ja) |
EP (1) | EP2946780B1 (ja) |
JP (1) | JP5805891B2 (ja) |
CN (1) | CN104271134B (ja) |
BR (1) | BR112014027231A2 (ja) |
CY (1) | CY1119159T1 (ja) |
DK (1) | DK2946780T3 (ja) |
ES (1) | ES2622568T3 (ja) |
HK (1) | HK1205463A1 (ja) |
HR (1) | HRP20170571T1 (ja) |
LT (1) | LT2946780T (ja) |
PL (1) | PL2946780T3 (ja) |
PT (1) | PT2946780T (ja) |
RS (1) | RS56032B1 (ja) |
RU (1) | RU2654703C2 (ja) |
SI (1) | SI2946780T1 (ja) |
WO (1) | WO2014112530A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018051971A1 (ja) * | 2016-09-13 | 2018-03-22 | 富士フイルム株式会社 | Mll関連白血病の予防または治療のための医薬、方法、使用及び化合物 |
WO2019082898A1 (ja) | 2017-10-27 | 2019-05-02 | 富士フイルム株式会社 | 5-ヒドロキシ-1h-イミダゾール-4-カルボキサミド・3/4水和物の製造方法 |
WO2020049786A1 (ja) * | 2018-09-03 | 2020-03-12 | 富士フイルム株式会社 | 組み合わせ医薬、ピリミジン代謝拮抗剤の耐性化の予防または抑制薬、および疾患の処置方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2937365C (en) | 2016-03-29 | 2018-09-18 | F. Hoffmann-La Roche Ag | Granulate formulation of 5-methyl-1-phenyl-2-(1h)-pyridone and method of making the same |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5332124A (en) | 1976-09-07 | 1978-03-27 | Sumitomo Chem Co Ltd | Carcinostatic agent |
US4181731A (en) * | 1976-09-07 | 1980-01-01 | Sumitomo Chemical Company, Limited | Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole |
JPS5824569A (ja) | 1981-08-05 | 1983-02-14 | Sumitomo Chem Co Ltd | イミダゾ−ル誘導体の精製方法 |
JPH0137376B2 (ja) | 1984-03-05 | 1989-08-07 | Sumitomo Pharma | |
JPH09208468A (ja) * | 1996-02-02 | 1997-08-12 | Dainippon Pharmaceut Co Ltd | p−クロロ−N−(2−モルホリノエチル)ベンズアミドを含有する錠剤 |
JP2007186470A (ja) * | 2006-01-16 | 2007-07-26 | Ss Pharmaceut Co Ltd | 圧縮成型製剤 |
WO2009035168A1 (ja) | 2007-09-14 | 2009-03-19 | Mbr Co., Ltd. | 4-カルバモイル-5-ヒドロキシ-イミダゾール誘導体のスルホン酸塩化合物 |
EP2407166A1 (en) * | 2009-03-13 | 2012-01-18 | Toyama Chemical Co., Ltd. | Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH048468A (ja) * | 1990-04-27 | 1992-01-13 | Sanshin:Kk | ワーク研摩機 |
AU2005297923B2 (en) * | 2004-10-25 | 2010-12-23 | Japan Tobacco Inc. | Solid medicinal preparation improved in solubility and stability and process for producing the same |
FR2903695B1 (fr) * | 2006-07-13 | 2008-10-24 | Merck Sante Soc Par Actions Si | Utilisation de derives d'imidazole activateurs de l'ampk, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
-
2014
- 2014-01-15 CN CN201480001101.9A patent/CN104271134B/zh not_active Expired - Fee Related
- 2014-01-15 PL PL14740552T patent/PL2946780T3/pl unknown
- 2014-01-15 WO PCT/JP2014/050591 patent/WO2014112530A1/ja active Application Filing
- 2014-01-15 DK DK14740552.6T patent/DK2946780T3/en active
- 2014-01-15 LT LTEP14740552.6T patent/LT2946780T/lt unknown
- 2014-01-15 BR BR112014027231A patent/BR112014027231A2/pt not_active Application Discontinuation
- 2014-01-15 RU RU2014143976A patent/RU2654703C2/ru not_active IP Right Cessation
- 2014-01-15 PT PT147405526T patent/PT2946780T/pt unknown
- 2014-01-15 RS RS20170377A patent/RS56032B1/sr unknown
- 2014-01-15 EP EP14740552.6A patent/EP2946780B1/en active Active
- 2014-01-15 JP JP2014557486A patent/JP5805891B2/ja active Active
- 2014-01-15 ES ES14740552.6T patent/ES2622568T3/es active Active
- 2014-01-15 SI SI201430172A patent/SI2946780T1/sl unknown
- 2014-10-30 US US14/528,768 patent/US9248102B2/en active Active
-
2015
- 2015-06-26 HK HK15106090.9A patent/HK1205463A1/zh not_active IP Right Cessation
-
2017
- 2017-04-11 HR HRP20170571TT patent/HRP20170571T1/hr unknown
- 2017-04-11 CY CY20171100434T patent/CY1119159T1/el unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5332124A (en) | 1976-09-07 | 1978-03-27 | Sumitomo Chem Co Ltd | Carcinostatic agent |
US4181731A (en) * | 1976-09-07 | 1980-01-01 | Sumitomo Chemical Company, Limited | Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole |
JPS5824569A (ja) | 1981-08-05 | 1983-02-14 | Sumitomo Chem Co Ltd | イミダゾ−ル誘導体の精製方法 |
JPH0137376B2 (ja) | 1984-03-05 | 1989-08-07 | Sumitomo Pharma | |
JPH09208468A (ja) * | 1996-02-02 | 1997-08-12 | Dainippon Pharmaceut Co Ltd | p−クロロ−N−(2−モルホリノエチル)ベンズアミドを含有する錠剤 |
JP2007186470A (ja) * | 2006-01-16 | 2007-07-26 | Ss Pharmaceut Co Ltd | 圧縮成型製剤 |
WO2009035168A1 (ja) | 2007-09-14 | 2009-03-19 | Mbr Co., Ltd. | 4-カルバモイル-5-ヒドロキシ-イミダゾール誘導体のスルホン酸塩化合物 |
EP2407166A1 (en) * | 2009-03-13 | 2012-01-18 | Toyama Chemical Co., Ltd. | Tablet and granulated powder containing 6-fluoro-3-hydroxy-2-pyrazinecarboxamide |
Non-Patent Citations (4)
Title |
---|
"Strategy and new technology for preparation of pharmaceutical formulations (Iyakuhin Seizaika Horyaku to Shin-gijutsu)", 2007, CMC PUBLISHING, article "chapter 2", pages: 47 |
J. PHARM. PHARMACEUT. SCI., vol. 8, 2005, pages 76 - 93 |
JPN. J. PHARM. HEALTH CARE SCI., vol. 32, 2006, pages 842 - 848 |
See also references of EP2946780A4 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018051971A1 (ja) * | 2016-09-13 | 2018-03-22 | 富士フイルム株式会社 | Mll関連白血病の予防または治療のための医薬、方法、使用及び化合物 |
WO2019082898A1 (ja) | 2017-10-27 | 2019-05-02 | 富士フイルム株式会社 | 5-ヒドロキシ-1h-イミダゾール-4-カルボキサミド・3/4水和物の製造方法 |
WO2020049786A1 (ja) * | 2018-09-03 | 2020-03-12 | 富士フイルム株式会社 | 組み合わせ医薬、ピリミジン代謝拮抗剤の耐性化の予防または抑制薬、および疾患の処置方法 |
Also Published As
Publication number | Publication date |
---|---|
DK2946780T3 (en) | 2017-05-08 |
CY1119159T1 (el) | 2018-02-14 |
RU2654703C2 (ru) | 2018-05-22 |
BR112014027231A2 (pt) | 2017-06-27 |
CN104271134A (zh) | 2015-01-07 |
CN104271134B (zh) | 2016-06-29 |
HRP20170571T1 (hr) | 2017-08-11 |
EP2946780B1 (en) | 2017-03-01 |
JP5805891B2 (ja) | 2015-11-10 |
EP2946780A1 (en) | 2015-11-25 |
PL2946780T3 (pl) | 2017-07-31 |
US20150057324A1 (en) | 2015-02-26 |
SI2946780T1 (sl) | 2017-05-31 |
HK1205463A1 (zh) | 2015-12-18 |
EP2946780A4 (en) | 2016-06-08 |
RU2014143976A (ru) | 2016-05-27 |
JPWO2014112530A1 (ja) | 2017-01-19 |
US9248102B2 (en) | 2016-02-02 |
RS56032B1 (sr) | 2017-09-29 |
PT2946780T (pt) | 2017-04-26 |
LT2946780T (lt) | 2017-06-12 |
ES2622568T3 (es) | 2017-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5583659B2 (ja) | 6−フルオロ−3−ヒドロキシ−2−ピラジンカルボキサミド含有錠剤および造粒末 | |
TWI702953B (zh) | 包含azd9291之醫藥組合物及錠劑以及其用途 | |
KR102070581B1 (ko) | 1-(3-(2-(1-벤조티오펜-5-일)에톡시)프로필)아제티딘-3-올 또는 그 염을 함유하는 고형 의약 조성물 | |
WO2007018192A1 (ja) | 口腔内崩壊錠剤 | |
WO2011019043A1 (ja) | 2種以上の粒子を含有する口腔内速崩壊錠 | |
TWI812602B (zh) | 含二胺衍生物之口腔崩散錠及其製造方法 | |
JP5805891B2 (ja) | 5−ヒドロキシ−1h−イミダゾール−4−カルボキサミドを含有する錠剤 | |
EP2022497B1 (en) | Oral composition comprising 3-[5-[4-(cyclopentyloxy) -2-hydroxybenzoyl]-2-](3-hydroxy-1,2-benzisoxazol-6- yl)methoxy¨phenyl¨propionic acid or salt thereof | |
JPWO2020090970A1 (ja) | 抗腫瘍剤を含む医薬組成物 | |
JP6112696B1 (ja) | ソリスロマイシンを含む錠剤 | |
WO2013081044A1 (ja) | 1-シクロプロピル-8-(ジフルオロメトキシ)-7-[(1r)-1-メチル-2,3-ジヒドロ-1h-イソインドール-5-イル]-4-オキソ-1,4-ジヒドロキノリン-3-カルボン酸のメタンスルホン酸塩水和物含有錠剤 | |
JP2020196713A (ja) | エドキサバンを含有する口腔内崩壊錠 | |
JPWO2020090971A1 (ja) | 抗腫瘍剤を含む錠剤 | |
WO2021132438A1 (ja) | ピロールカルボキサミドを含む口腔内崩壊錠 | |
JP2022072050A (ja) | エドキサバンを含有する口腔内崩壊錠 | |
JPWO2017188361A1 (ja) | トスフロキサシントシル酸塩を含む錠剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14740552 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2014740552 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014740552 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2014143976 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112014027231 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2014557486 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: P-2017/0377 Country of ref document: RS |
|
ENP | Entry into the national phase |
Ref document number: 112014027231 Country of ref document: BR Kind code of ref document: A2 Effective date: 20141030 |